Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
D015120:6-Aminonicotinamide / Q000009:adverse effects*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001418:Baclofen / Q000494:pharmacology; D001921:Brain / Q000378:metabolism; D001923:Brain Chemistry; D001971:Bromocriptine / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D004195:Disease Models, Animal; D004298:Dopamine / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D004576:Electromyography; D005942:Gluconates / Q000134:cerebrospinal fluid; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use; D008297:Male; D009046:Motor Neurons / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012313:RNA / Q000096:biosynthesis; D051381:Rats; D012110:Reserpine / Q000009:adverse effects; D013116:Spinal Cord / Q000032:analysis; D013403:Sugar Phosphates / Q000134:cerebrospinal fluid
D014150:Antipsychotic Agents; D005942:Gluconates; D013403:Sugar Phosphates; D009536:Niacinamide; D015120:6-Aminonicotinamide; D001971:Bromocriptine; D007980:Levodopa; D012313:RNA; D012110:Reserpine; D008090:Lisuride; D001418:Baclofen; D004298:Dopamine